Laboratory of Intestinal Adaptation and Recovery, The Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
PLoS One. 2012;7(9):e45221. doi: 10.1371/journal.pone.0045221. Epub 2012 Sep 12.
BACKGROUND/AIMS: Dietary supplementation with transforming growth factor-beta (TGF-β) has been proven to minimize intestinal damage and facilitate regeneration after mucosal injury. In the present study, we evaluated the effects of oral TGF-β2 supplementation on intestinal structural changes, enterocyte proliferation and apoptosis following methotrexate (MTX)-induced intestinal damage in a rat and in a cell culture model.
Caco-2 cells were treated with MTX and were incubated with increasing concentrations of TGF-β2. Cell apoptosis was assessed using FACS analysis by annexin staining and cell viability was monitored using Trypan Blue assay. Male rats were divided into four experimental groups: Control rats, CONTR- TGF-β rats were treated with diet enriched with TGF-β2, MTX rats were treated with a single dose of methotrexate, and MTX- TGF-β rats were treated with diet enriched with TGF-β2. Intestinal mucosal damage, mucosal structural changes, enterocyte proliferation and enterocyte apoptosis were determined at sacrifice. Real Time PCR and Western blot were used to determine bax and bcl-2 mRNA, p-ERK, β-catenin, IL-1B and bax protein expression.
Treatment of MTX-pretreated Caco-2 cells with TGF-B2 resulted in increased cell viability and decreased cell apoptosis. Treatment of MTX-rats with TGF-β2 resulted in a significant increase in bowel and mucosal weight, DNA and protein content, villus-height (ileum), crypt-depth (jejunum), decreased intestinal-injury score, decreased level of apoptosis and increased cell proliferation in jejunum and ileum compared to the untreated MTX group. MTX-TGF-β2 rats demonstrated a lower bax mRNA and protein levels as well as increased bcl-2 mRNA levels in jejunum and ileum compared to MTX group. Treatment with TGF-β2 also led to increased pERK, IL-1B and β-catenin protein levels in intestinal mucosa.
Treatment with TGF-β2 prevents mucosal-injury, enhances p-ERK and β-catenin induced enterocyte proliferation, inhibits enterocyte apoptosis and improves intestinal recovery following MTX-induced intestinal-mucositis in rats.
背景/目的:转化生长因子-β(TGF-β)的膳食补充已被证明可最大程度地减少肠损伤并促进黏膜损伤后的再生。在本研究中,我们评估了口服 TGF-β2 补充对 MTX 诱导的大鼠和细胞培养模型中肠损伤后肠结构变化、肠上皮细胞增殖和凋亡的影响。
用 MTX 处理 Caco-2 细胞,并在不同浓度的 TGF-β2 中孵育。通过 Annexin 染色的 FACS 分析评估细胞凋亡,通过台盼蓝测定法监测细胞活力。雄性大鼠分为四组:对照组、CONTR-TGF-β 组用富含 TGF-β2 的饮食治疗,MTX 组用单次 MTX 治疗,MTX-TGF-β 组用富含 TGF-β2 的饮食治疗。在处死时确定肠黏膜损伤、黏膜结构变化、肠上皮细胞增殖和肠上皮细胞凋亡。使用实时 PCR 和 Western blot 确定 bax 和 bcl-2 mRNA、p-ERK、β-catenin、IL-1B 和 bax 蛋白的表达。
用 TGF-B2 处理 MTX 预处理的 Caco-2 细胞可增加细胞活力并减少细胞凋亡。与未处理的 MTX 组相比,用 TGF-β2 治疗 MTX 大鼠可显著增加肠和黏膜重量、DNA 和蛋白质含量、绒毛高度(回肠)、隐窝深度(空肠)、降低肠损伤评分、降低空肠和回肠的凋亡水平并增加细胞增殖。与 MTX 组相比,MTX-TGF-β2 大鼠的 jejunum 和 ileum 中 bax mRNA 和蛋白水平降低,bcl-2 mRNA 水平升高。TGF-β2 治疗还导致肠黏膜中 pERK、IL-1B 和 β-catenin 蛋白水平升高。
用 TGF-β2 治疗可预防黏膜损伤,增强 MTX 诱导的肠上皮细胞增殖,抑制肠上皮细胞凋亡,并改善大鼠 MTX 诱导的肠黏膜炎后的肠恢复。